{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:26:19Z","timestamp":1793219179065,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"unspecified","delay-in-days":62,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019832","name":"Gal\u00e1pagos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,1,5]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major adverse cardiovascular events (MACE), venous thromboembolism (VTE) and malignancies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were integrated from all phase II and III trials that have investigated filgotinib 100 mg or 200 mg once daily in RA and UC to date.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Analyses represent &gt;12\u2009500 (RA) and &gt;2800 (UC) patient-years of exposure (PYE) to filgotinib. Incidences of AEI in the integrated analysis population were low. Modest numerical increases in incidence rates occurred in patients aged \u226565 years, including MACE (patients with RA), and malignancies (excluding non-melanoma skin cancer (NMSC)) and NMSC (patients with RA or UC). VTE was rare; in patients with RA aged \u226565 years receiving filgotinib 200 mg, exposure-adjusted incidence rate (95% CI) for VTE was 0.3 (0.1, 0.8)\/100 PYE; no VTE events occurred in patients with UC aged \u226565 years. In patients with RA aged \u226565 years, MACE incidence rates were identical between filgotinib 100 mg and 200 mg; rates of malignancies and NMSC were numerically higher with 200 mg compared with 100 mg.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Data are consistent with previous overall safety analyses demonstrating low rates of AEI in the overall study population. Numerically increased rates of AEI occurred in patients aged \u226565 years; further data are needed to assess the effect of CV risk factors. Overall, in this analysis, there was no consistent filgotinib dose effect on AEI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-005033","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:06:16Z","timestamp":1741115176000},"page":"e005033","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct01888874","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01894516","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02889796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02873936","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02886728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02065700","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03025308","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02914522","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02914535","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03025308","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02914535","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02065700","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04871919","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05817942","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-5417","authenticated-orcid":false,"given":"Xavier","family":"Mariette","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Universit\u00e9 Paris-Saclay, AP-HP-H\u00f4pital Bic\u00eatre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Borchmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[{"name":"Department of Oncology, UZ Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Szekanecz","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-7019","authenticated-orcid":false,"given":"Christina","family":"Charles-Schoeman","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital Schleswig Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-8609","authenticated-orcid":false,"given":"Ernest HS","family":"Choy","sequence":"additional","affiliation":[{"name":"Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, INFINY Institute, FHU-CURE, INSERM NGERE, Nancy University Hospital, Vandoeuvre-Les-Nancy, France"},{"name":"Groupe Hospitalier priv\u00e9 Ambroise Par\u00e9 \u2013 Hartmann, Neuilly sur Seine, France"},{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Rheumatology\/Clinical Immunology, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"ten Cate","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine and Biochemistry and CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-3073","authenticated-orcid":false,"given":"Ren\u00e9","family":"Westhovens","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Janneke","family":"van der Woude","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund V","family":"Ekoka Omoruyi","sequence":"additional","affiliation":[{"name":"Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Faes","sequence":"additional","affiliation":[{"name":"Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Masior","sequence":"additional","affiliation":[{"name":"Galapagos GmbH, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Van Hoek","sequence":"additional","affiliation":[{"name":"Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Watson","sequence":"additional","affiliation":[{"name":"Galapagos Biotech, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rudolph","sequence":"additional","affiliation":[{"name":"Galapagos Biopharma GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stallmach","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Jena University Hospital, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"2025090312230575000_11.1.e005033.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2025090312230575000_11.1.e005033.2","first-page":"201","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims database","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025090312230575000_11.1.e005033.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276"},{"key":"2025090312230575000_11.1.e005033.4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090312230575000_11.1.e005033.5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/apt.17816","article-title":"Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis","volume":"59","author":"Panaccione","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090312230575000_11.1.e005033.6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/apt.17674","article-title":"Integrated safety analysis of filgotinib for ulcerative colitis: results from SELECTION and SELECTIONLTE","volume":"58","author":"Schreiber","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090312230575000_11.1.e005033.7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus kinase inhibitors in inflammatory bowel diseases","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"key":"2025090312230575000_11.1.e005033.8","doi-asserted-by":"crossref","first-page":"S755","DOI":"10.1093\/ecco-jcc\/jjaa017","article-title":"JAK inhibitors safety in ulcerative colitis: practical implications","volume":"14","author":"Agrawal","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2025090312230575000_11.1.e005033.9","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2023-102400"},{"key":"2025090312230575000_11.1.e005033.10","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000952996.56641.f9","article-title":"S839 Biologic and small molecule therapies are not associated with increased major adverse cardiovascular events (MACE) in IBD: a propensity matched cohort study","volume":"118","author":"Qapaja","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2025090312230575000_11.1.e005033.11","first-page":"S","article-title":"720 Oral small molecules are not associted with increased cancer rates in IBD patients","volume":"166","author":"Qapaja","year":"2024","journal-title":"Gastroenterology"},{"key":"2025090312230575000_11.1.e005033.12","unstructured":"European Medicines Agency . Jyseleca: EPAR - product information. 2023. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jyseleca-epar-product-information_en.pdf [Accessed 8 Feb 2024]."},{"key":"2025090312230575000_11.1.e005033.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2021.1902617","article-title":"Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: an overview from clinical trials","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2025090312230575000_11.1.e005033.14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/ard-2024-225759","article-title":"Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years","volume":"83","author":"Burmester","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025090312230575000_11.1.e005033.15","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115507"},{"key":"2025090312230575000_11.1.e005033.16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"key":"2025090312230575000_11.1.e005033.17","doi-asserted-by":"crossref","first-page":"1759720X211030809","DOI":"10.1177\/1759720X211030809","article-title":"Factors associated with risk of major adverse cardiovascular events in patients with rheumatoid arthritis: a nationwide, population-based, case-control study","volume":"13","author":"Chen","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025090312230575000_11.1.e005033.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090312230575000_11.1.e005033.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209285"},{"key":"2025090312230575000_11.1.e005033.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235142","article-title":"Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: a population-based cohort study in northeastern Italy","volume":"15","author":"Taborelli","year":"2020","journal-title":"PLOS One"},{"key":"2025090312230575000_11.1.e005033.21","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cgh.2020.08.015","article-title":"The risk of extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies","volume":"19","author":"Lo","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090312230575000_11.1.e005033.22","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.4.526"},{"key":"2025090312230575000_11.1.e005033.23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/apt.16677","article-title":"Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962-1987 and followed until 2017 in a Danish population-based inception cohort","volume":"55","author":"Burisch","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090312230575000_11.1.e005033.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.08.005"},{"key":"2025090312230575000_11.1.e005033.25","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40266-017-0498-y","article-title":"Risk of malignancy in a nationwide cohort of elderly inflammatory bowel disease patients","volume":"34","author":"Khan","year":"2017","journal-title":"Drugs Aging"},{"key":"2025090312230575000_11.1.e005033.26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41395-018-0360-9","article-title":"Malignancies in inflammatory bowel disease: frequency, incidence and risk factors-results from the Swiss IBD cohort study","volume":"114","author":"Scharl","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2025090312230575000_11.1.e005033.27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"2025090312230575000_11.1.e005033.28","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.3937"},{"key":"2025090312230575000_11.1.e005033.29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041083","article-title":"Management of inflammatory bowel disease in patients with current or past malignancy","volume":"15","author":"Poullenot","year":"2023","journal-title":"Cancers"},{"key":"2025090312230575000_11.1.e005033.30","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41423-019-0320-3","article-title":"JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis","volume":"17","author":"Nocturne","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2025090312230575000_11.1.e005033.31","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X16643340"},{"key":"2025090312230575000_11.1.e005033.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224185"},{"key":"2025090312230575000_11.1.e005033.33","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s40744-023-00599-1","article-title":"Effect of filgotinib on body mass index (BMI) and effect of baseline bmi on the efficacy and safety of filgotinib in rheumatoid arthritis","volume":"10","author":"Balsa","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025090312230575000_11.1.e005033.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01017-x"},{"key":"2025090312230575000_11.1.e005033.35","unstructured":"US National Library of Medicine . Long term extension study to assess the safety and efficacy of filgotinib in adults with rheumatoid arthritis (FINCH 4). 2017. Available: https:\/\/clinicaltrials.gov\/study\/NCT03025308 [Accessed 27 Feb 2024]."},{"key":"2025090312230575000_11.1.e005033.36","unstructured":"US National Library of Medicine . Filgotinib in long-term extension study of adults with ulcerative colitis (SELECTIONLTE). 2016. Available: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02914535 [Accessed 27 Feb 2024]."},{"key":"2025090312230575000_11.1.e005033.37","unstructured":"US National Library of Medicine . Long-term follow-up study of GLPG0634 in active rheumatoid arthritis patients (DARWIN 3). 2014. Available: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02065700 [Accessed 27 Feb 2024]."},{"key":"2025090312230575000_11.1.e005033.38","unstructured":"US National Library of Medicine . Prospective observational study of filgotinib in subjects with rheumatoid arthritis (FILOSOPHY). 2021. Available: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04871919 [Accessed 27 Feb 2024]."},{"key":"2025090312230575000_11.1.e005033.39","unstructured":"US National Library of Medicine . Prospective observational study of effectiveness and safety of filgotinib in participants with ulcerative colitis (UC) (GALOCEAN). 2023. Available: https:\/\/clinicaltrials.gov\/study\/NCT05817942 [Accessed 27 Feb 2024]."},{"key":"2025090312230575000_11.1.e005033.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221051"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-005033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:23:17Z","timestamp":1756927397000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-005033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,4]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/rmdopen-2024-005033"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-005033","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}